NAD+ and Longevity: What the Science Actually Says

NAD+ has become the centrepiece of the longevity conversation, which means the science and the marketing have drifted a long way apart. Both statements below are true, and holding them together is the whole task:

NAD+ decline with age is one of the better-established observations in ageing biology. Whether restoring NAD+ meaningfully changes ageing outcomes in humans is not established.

What NAD+ does

Nicotinamide adenine dinucleotide is a coenzyme present in every cell, running two distinct classes of job.

Redox metabolism. NAD+/NADH cycling carries electrons through glycolysis, the TCA cycle and oxidative phosphorylation. Without it, ATP production stops. This pool is recycled, not consumed.

Signalling. A separate set of enzymes consumes NAD+ as a substrate:

• Sirtuins (SIRT1–7) — deacetylases involved in metabolic regulation, mitochondrial biogenesis and DNA repair
• PARPs — DNA damage repair, which becomes a major NAD+ sink as damage accumulates
• CD38 — an NADase whose expression rises with age and inflammation

This second category is why NAD+ became a longevity target. The signalling enzymes are directly involved in processes that deteriorate with age.

Why levels fall

Two forces, both worsening with age:

• Increased consumption — more DNA damage means more PARP activity; chronic inflammation drives CD38 up
• Reduced salvage capacity — the NAMPT-driven recycling pathway becomes less efficient

The result is a squeeze from both directions.

The precursors

NAD+ itself is poorly suited to oral administration — it's large, charged and unstable in the gut. Research has therefore concentrated on precursors:

• NR (nicotinamide riboside) — converted via NRK enzymes
• NMN (nicotinamide mononucleotide) — one step closer to NAD+
• Niacin / nicotinamide — the classical vitamin B3 forms
• Direct NAD+ in research settings, bypassing the oral absorption problem entirely

What human studies show

Clinical work on NR and NMN has been reasonably consistent on one point and disappointing on another.

Consistent: precursors raise blood NAD+ levels. That part works, dose-dependently, and is well replicated.

Disappointing: demonstrating that the increase translates into functional benefit has been much harder. Trials have reported modest or mixed effects on insulin sensitivity, muscle function, aerobic capacity and inflammatory markers. Sample sizes are small, durations are short, and endpoints vary widely between studies.

The gap between "biomarker moved" and "outcome improved" is the central unresolved question in the field.

Three complications worth knowing

Tissue distribution. Blood NAD+ is easy to measure and may not represent muscle, brain or liver — the tissues the hypothesis actually cares about.

Compartmentalisation. Cytosolic, mitochondrial and nuclear NAD+ pools are regulated somewhat separately. Raising total NAD+ does not guarantee raising the pool that matters for a given mechanism.

Ceiling effects. In young, healthy subjects with adequate NAD+, adding more may do very little. The strongest signals in preclinical work come from models that were depleted to begin with — which suggests the intervention is corrective rather than enhancing.

How to read the field

The mechanistic case is strong. The intervention case is unproven. That's a normal and honest place for a research area to be roughly fifteen years into serious investigation.

For researchers, the productive questions are no longer "does NAD+ decline?" but which tissue, which pool, which population, and which endpoint. Studies that answer those specifically will be worth far more than another round of blood-level replication.

EVERKIND stocks NAD+ 1000mg for laboratory research use.

Disclaimer: This article is educational only. All compounds discussed are supplied strictly for laboratory research use and are not approved for human or veterinary use.